Akero Therapeutics Inc (NASDAQ:AKRO) — Market Cap & Net Worth
Market Cap & Net Worth: Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (NASDAQ:AKRO) has a market capitalization of $4.50 Billion ($4.50 Billion) as of June 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3855 globally and #1329 in its home market, demonstrating a 0.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akero Therapeutics Inc's stock price $54.65 by its total outstanding shares 82324445 (82.32 Million). Review Akero Therapeutics Inc (AKRO) total liabilities to assess the company's total debt and financial obligations.
Akero Therapeutics Inc Market Cap History: 2019 to 2025
Akero Therapeutics Inc's market capitalization history from 2019 to 2025. Data shows growth from $1.83 Billion to $4.50 Billion (18.38% CAGR).
Index Memberships
Akero Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.18% | #89 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.01% | #437 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.26% | #60 of 263 |
Weight: Akero Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Akero Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akero Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AKRO by Market Capitalization
Companies near Akero Therapeutics Inc in the global market cap rankings as of June 15, 2026.
Key companies related to Akero Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Akero Therapeutics Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, Akero Therapeutics Inc's market cap moved from $1.83 Billion to $ 4.50 Billion, with a yearly change of 18.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.50 Billion | +96.44% |
| 2024 | $2.29 Billion | +19.14% |
| 2023 | $1.92 Billion | -57.39% |
| 2022 | $4.51 Billion | +159.10% |
| 2021 | $1.74 Billion | -18.02% |
| 2020 | $2.12 Billion | +16.24% |
| 2019 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Akero Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.50 Billion USD |
| MoneyControl | $4.50 Billion USD |
| MarketWatch | $4.50 Billion USD |
| marketcap.company | $4.50 Billion USD |
| Reuters | $4.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more